Arvinas, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ARVN research report →
Companywww.arvinas.com
Arvinas, Inc. , a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC); ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer; and ARV-766 an investigational orally bioavailable PROTAC protein degrader for the treatment of men with mCRPC.
- CEO
- Randy Teel
- IPO
- 2018
- Employees
- 430
- HQ
- New Haven, CT, US
Price Chart
Valuation
- Market Cap
- $587.14M
- P/E
- -2.63
- P/S
- 6.57
- P/B
- 1.51
- EV/EBITDA
- -2.19
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 97.43%
- Op Margin
- -279.31%
- Net Margin
- -247.54%
- ROE
- -44.39%
- ROIC
- -46.80%
Growth & Income
- Revenue
- $262.60M · -0.30%
- Net Income
- $-80,800,000 · 59.38%
- EPS
- $-1.28 · 53.79%
- Op Income
- $-114,900,000
- FCF YoY
- -5.59%
Performance & Tape
- 52W High
- $14.51
- 52W Low
- $6.06
- 50D MA
- $10.71
- 200D MA
- $10.58
- Beta
- 1.80
- Avg Volume
- 1.09M
Get TickerSpark's AI analysis on ARVN
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 11, 26 | Saik Andrew | sell | 11,139 |
| May 11, 26 | Loomis David K | sell | 1,919 |
| May 11, 26 | Cacace Angela M | sell | 9,657 |
| May 11, 26 | Berkowitz Noah | sell | 11,108 |
| May 11, 26 | Teel Randy | sell | 9,657 |
| Mar 18, 26 | Berkowitz Noah | sell | 6,435 |
| Feb 26, 26 | Teel Randy | other | 147,179 |
| Mar 6, 26 | Morrison Briggs | buy | 20,000 |
| Feb 26, 26 | Loomis David K | other | 12,420 |
| Feb 26, 26 | Loomis David K | other | 18,504 |
Our ARVN Coverage
We haven't published any research on ARVN yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate ARVN Report →